Envestnet Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.08B Buy
1,175,177
+68,519
+6% +$69.5M 0.29% 62
2025
Q4
$1.19B Sell
1,106,658
-59,602
-5% -$57M 0.35% 58
2025
Q3
$890M Sell
1,166,260
-46,572
-4% -$34.7M 0.26% 69
2025
Q2
$945M Buy
1,212,832
+100,831
+9% +$78.4M 0.28% 66
2025
Q1
$918M Buy
1,112,001
+161,665
+17% +$135M 0.3% 66
2024
Q4
$734M Buy
950,336
+41,669
+5% +$34.5M 0.24% 71
2024
Q3
$805M Buy
908,667
+13,613
+2% +$12.2M 0.26% 66
2024
Q2
$810M Buy
895,054
+40,687
+5% +$32.5M 0.28% 63
2024
Q1
$665M Buy
854,367
+56,517
+7% +$40.2M 0.25% 72
2023
Q4
$465M Sell
797,850
-7,637
-0.9% -$4.46M 0.19% 95
2023
Q3
$433M Buy
805,487
+149,183
+23% +$76.9M 0.2% 95
2023
Q2
$308M Sell
656,304
-1,777,769
-73% -$746M 0.14% 123
2023
Q1
$218M Buy
2,434,073
+1,850,187
+317% +$624M 0.1% 168
2022
Q4
$214M Buy
583,886
+14,364
+3% +$5.09M 0.11% 171
2022
Q3
$184M Sell
569,522
-15,994
-3% -$5.07M 0.11% 175
2022
Q2
$190M Buy
585,516
+143,571
+32% +$43.1M 0.11% 179
2022
Q1
$127M Buy
441,945
+21,759
+5% +$5.6M 0.06% 260
2021
Q4
$116M Buy
420,186
+73,713
+21% +$18.7M 0.06% 288
2021
Q3
$80.1M Buy
346,473
+25,724
+8% +$6.35M 0.04% 339
2021
Q2
$73.6M Buy
320,749
+18,406
+6% +$3.7M 0.04% 353
2021
Q1
$56.5M Buy
302,343
+19,253
+7% +$3.77M 0.04% 378
2020
Q4
$47.8M Sell
283,090
-14,348
-5% -$2.14M 0.04% 362
2020
Q3
$44M Sell
297,438
-13,769
-4% -$2.13M 0.04% 334
2020
Q2
$51.1M Buy
311,207
+4,985
+2% +$765K 0.05% 274
2020
Q1
$42.5M Buy
306,222
+18,068
+6% +$2.48M 0.05% 265
2019
Q4
$37.9M Buy
288,154
+19,423
+7% +$2.25M 0.04% 327
2019
Q3
$30.1M Buy
268,731
+13,110
+5% +$1.46M 0.03% 368
2019
Q2
$28.3M Sell
255,621
-30,678
-11% -$3.61M 0.04% 359
2019
Q1
$37.1M Sell
286,299
-30,694
-10% -$3.73M 0.05% 276
2018
Q4
$36.7M Buy
316,993
+312,755
+7,380% +$34.9M 0.06% 239
2018
Q3
$455K Sell
4,238
-47,708
-92% -$4.77M ﹤0.01% 935
2018
Q2
$4.43M Sell
51,946
-1,542
-3% -$127K 0.01% 531
2018
Q1
$4.14M Sell
53,488
-171,369
-76% -$13.8M 0.01% 449
2017
Q4
$19M Buy
224,857
+7,162
+3% +$609K 0.04% 247
2017
Q3
$18.6M Buy
217,695
+1,003
+0.5% +$82.3K 0.04% 231
2017
Q2
$17.8M Buy
216,692
+2,686
+1% +$219K 0.05% 238
2017
Q1
$18M Buy
214,006
+26,352
+14% +$2.11M 0.06% 221
2016
Q4
$13.8M Buy
187,654
+55,767
+42% +$4.15M 0.05% 268
2016
Q3
$10.6M Sell
131,887
-125,738
-49% -$10.1M 0.04% 327
2016
Q2
$20.3M Buy
257,625
+47,259
+22% +$3.56M 0.08% 211
2016
Q1
$15.1M Sell
210,366
-6,264
-3% -$474K 0.07% 255
2015
Q4
$18.3M Buy
216,630
+25,942
+14% +$2.15M 0.08% 216
2015
Q3
$16M Sell
190,688
-39,053
-17% -$3.3M 0.08% 219
2015
Q2
$19.2M Sell
229,741
-22,210
-9% -$1.69M 0.09% 215
2015
Q1
$18.3M Buy
251,951
+226,268
+881% +$16.1M 0.09% 214
2014
Q4
$1.77M Sell
25,683
-842
-3% -$56.8K 0.02% 417
2014
Q3
$1.72M Buy
26,525
+6,245
+31% +$395K 0.02% 431
2014
Q2
$1.26M Buy
20,280
+1,225
+6% +$73.1K 0.01% 475
2014
Q1
$1.12M Buy
19,055
+320
+2% +$17.9K 0.01% 431
2013
Q4
$955K Buy
18,735
+1,355
+8% +$67.9K 0.01% 464
2013
Q3
$875K Sell
17,380
-434
-2% -$22.7K 0.01% 454
2013
Q2
$875K Buy
+17,814
New +$969K 0.01% 441

Other funds holding LLY

Envestnet Asset Management's LLY Position: Q1 2026 in Review

Envestnet Asset Management increased its Eli Lilly (LLY) stake by 6.2% in Q1 2026, buying an estimated $69.5M and bringing the position to 1,175,177 shares worth $1.08B. The position accounts for 0.29% of the portfolio, ranked #62.

Envestnet Asset Management first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.19B in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Envestnet Asset Management held 1,175,177 shares of Eli Lilly worth $1.08B as of Q1 2026.
  • Envestnet Asset Management bought 68,519 Eli Lilly shares in Q1 2026, an estimated $69.5M.
  • Eli Lilly made up 0.29% of Envestnet Asset Management's portfolio in Q1 2026, its #62 holding.
  • Envestnet Asset Management first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Envestnet Asset Management's Eli Lilly position peaked at $1.19B in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.